8-K: Arcus Biosciences Updates ARC-20 Data, Expands Pipeline

Arcus Biosciences presented updated Phase 1/1b data for casdatifan in metastatic clear cell renal cell carcinoma and unveiled new immunology and inflammation programs with clinical studies expected in 2026.

Summary

• Updated data from the ARC-20 Phase 1/1b study of casdatifan monotherapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) was presented, with a data cutoff date of August 15, 2025.
• A pooled analysis (n=121) of efficacy-evaluable patients showed a median Progression-Free Survival (PFS) of 12.2 months [95% CI: 9.4, 20.6].
• The pooled analysis demonstrated a confirmed Objective Response Rate (ORR) of 31% [95% CI: 23, 40], including 1% (1 patient) achieving a Complete Response and 31% (37 patients) achieving a Partial Response.
• The Disease Control Rate (DCR) in the pooled analysis was 81% (98 patients) [95% CI: 63, 88].
• Casdatifan exhibited an acceptable and manageable safety profile across all doses, with no unexpected safety signals observed in the safety-evaluable population (n=127).
• New research programs in immunology and inflammation were disclosed, with the expectation to initiate the first clinical study from one or more of these programs in 2026.

Sentiment

Score: 8

Explanation: The updated ARC-20 data shows promising efficacy and a manageable safety profile for casdatifan in a challenging indication. The strategic expansion into immunology and inflammation with multiple new programs and a clear timeline for clinical initiation in 2026 significantly enhances the company's long-term growth prospects and pipeline diversification.

Positives

• Strong efficacy signals for casdatifan in the ARC-20 study for mccRCC, with a pooled median PFS of 12.2 months and a confirmed ORR of 31%.
• Casdatifan demonstrated an acceptable and manageable safety profile, with no unexpected safety signals observed.
• Strategic expansion into immunology and inflammation with multiple advanced discovery and preclinical programs, offering future growth opportunities and pipeline diversification.
• Expectation to initiate the first clinical study from new immunology and inflammation programs in 2026, indicating clear pipeline progression.

Negatives

• Some Progression-Free Survival (PFS) data points were 'Not Estimable' (NE) for specific cohorts (100mg QD and 150mg QD), indicating insufficient maturity for precise estimation in those groups.
• Grade 3 Treatment-Emergent Adverse Events (TEAEs) related to casdatifan, such as Anemia (41% pooled) and Hypoxia (11% pooled), were observed, though deemed manageable.
• A small percentage of patients (3% pooled) discontinued treatment due to casdatifan-related TEAEs.

Risks

• Interim data may not be replicated in other studies evaluating casdatifan.
• Risks associated with manufacturing or supplying product for clinical trials evaluating casdatifan.
• Adverse data from toxicology studies could affect the ability to advance development candidates from immunology and inflammation programs.
• Uncertainties in timelines associated with the conduct of clinical studies and with respect to the regulatory approval process.
• Changes in the competitive landscape for the Company's programs.
• Inherent uncertainty associated with pharmaceutical product development and clinical trials.

Future Outlook

The Company expects to initiate the first clinical study from one or more of its new immunology and inflammation programs in 2026. The unconfirmed objective response rate of ARC-20 is also a forward-looking statement.

Management Comments

• Management presented updated data from the ARC-20 study and shared new research programs in immunology and inflammation, indicating a focus on pipeline expansion and progression.

Industry Context

The oncology and immunology/inflammation fields are highly competitive. Positive Phase 1/1b data for casdatifan in metastatic clear cell renal cell carcinoma, a challenging cancer, positions Arcus Biosciences favorably, especially given the manageable safety profile. The expansion into immunology and inflammation with multiple novel targets aligns with broader industry trends of diversifying pipelines and addressing unmet needs in chronic inflammatory diseases.

Comparison to Industry Standards

• The median PFS of 12.2 months and confirmed ORR of 31% for casdatifan monotherapy in metastatic clear cell renal cell carcinoma (mccRCC) are notable for a monotherapy in this setting. For comparison, standard-of-care first-line treatments for advanced RCC often involve combinations of VEGF inhibitors and immune checkpoint inhibitors, which can achieve higher ORRs and PFS.
• For example, pembrolizumab plus lenvatinib showed a median PFS of 23.9 months and ORR of 71% in first-line advanced RCC (KEYNOTE-581/CLEAR study), while nivolumab plus ipilimumab showed a median PFS of 11.6 months and ORR of 42% in intermediate/poor-risk patients (CheckMate 214).
• While direct monotherapy comparisons are difficult, casdatifan's profile suggests potential, particularly if it can be combined effectively or used in specific patient populations. The safety profile appears manageable, which is crucial for long-term treatment.

Stakeholder Impact

• **Shareholders:** Positive clinical data and pipeline expansion could lead to increased investor confidence and potential share price appreciation.
• **Patients:** Promising efficacy and safety data for casdatifan offers hope for a new treatment option for metastatic clear cell renal cell carcinoma. New I&I programs could address unmet needs in other diseases.
• **Employees:** Expansion of research programs and clinical development indicates potential for growth and new opportunities within the company.

Next Steps

• Further evaluation of casdatifan in ongoing or future clinical studies, potentially in combination therapies.
• Initiation of the first clinical study from one or more immunology and inflammation programs in 2026.
• Continued development of MRGPRX2, TNF-a (TNFR1), CCR6, CD89, and CD40L small-molecule inhibitors and monoclonal antibodies.

Key Dates

Recommendation

The updated Phase 1/1b data for casdatifan in metastatic clear cell renal cell carcinoma demonstrates compelling efficacy (12.2 months median PFS, 31% ORR) and a manageable safety profile for a monotherapy in this difficult-to-treat population. This positive clinical progress significantly de-risks the asset. Furthermore, the strategic expansion into immunology and inflammation with multiple novel preclinical programs, targeting significant market opportunities and aiming for clinical initiation in 2026, provides a strong foundation for future growth and pipeline diversification. These developments collectively suggest a strong long-term value proposition for Arcus Biosciences.

Keywords

Arcus Biosciences, RCUS, casdatifan, ARC-20, renal cell carcinoma, mccRCC, oncology, immunology, inflammation, clinical trial, Phase 1/1b, drug development, biotech, pharmaceutical